Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma

Central Nervous System Tumors

A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

Lancet Oncol

Karschnia P, Young JS, Wijnenga MMJ, Sciortino T, Teske N, Corell A, Wagner A, Youssef G, Park YW, Häni L, Jünger ST, Dono A, Ehret F, Mireles EEM, Neidert N, Bruno F, Tuchek CA, van der Vaart T, Rossi M, Nibali MC, Gay L, Gramelt A, Tandon N, Ahn SS, Chang JH, Weller M, Vincent AJPE, Goldbrunner R, Cahill DP, Huang RY, Raabe A, Meyer B, Beck J, Molinaro AM, Chang SM, Vogelbaum MA, Rudà R, Vik-Mo EO, Dietrich J, Esquenazi Y, Grau SJ, Wen PY, Jakola AS, Schnell O, Bello L, van den Bent MJ, Hervey-Jumper S, Berger MS, Tonn JC

doi: 10.1016/S1470-2045(25)00534-0

Central Nervous System Tumors

Distinct molecular profile and outcome of oligodendroglioma, IDH-mutant, 1p/19q-codeleted and TERTp-wildtype: a grade 1 oligodendroglioma of young patients?

Neuro Oncol

Nozzoli F, Rahmanzade R, Schmid S, Schweizer L, Schrimpf D, Friedel D, Göbel K, Reuss DE, Banan R, Sievers P, Pusch S, Bogumil H, Hinz F, Suwala AK, Aras FK, Friedrich L, Osella-Abate S, Ricci AA, Macciotta A, Simon T, Fleischhack G, Keyvani K, Hansford JR, Khuong-Quang DA, Schucht P, Maragkou T, Juratli TA, Meinhardt M, Zechel S, Stadelmann C, Coras R, Sakowitz OW, Goeppert B, Schittenhelm J, Etminan N, Ratliff M, Herold-Mende C, Pfister SM, Wick W, Krieg SM, von Deimling A, Sahm F, Bertero L

doi: 10.1093/neuonc/noaf141

ASH 2025

Lymphoma

Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel

Leukemia

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

Leukemia

Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, López-Esteban M, Martínez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S

doi: 10.1038/s41375-025-02814-0

Lung, Respiratory and Thoracic Cancer

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Lung Cancer

Zhang Q, Yang Y, Xie M, Zhou Z, Wu H, Zhai W, Chen Y, Chen K, Zhou S, Li H, Fan Y

doi: 10.1016/j.lungcan.2025.108616

Gynecologic Cancer

The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma

Eur J Cancer

Li Z, Peng J, Zhang B, Zhao C, Chen Z, Xiao H, Zhang Z, Ma X, Gao F, Xin R, Wang W, Wang S, Tang L, Zhang Y, Kong B, Li L, Yin A

doi: 10.1016/j.ejca.2025.115258

Gastrointestinal Cancer

Prognostic significance of pre-treatment immune-inflammation biomarkers in anal cancer: A study combining real-world data and a meta-analysis

Int J Cancer

Wind KL, Steffensen JH, Jakobsen AV, Kronborg C, Spindler KG

doi: 10.1002/ijc.35404

Breast Cancer

Prognostic significance and predictive value of circulating tumor cells in invasive lobular breast carcinoma - an exploratory analysis of the STIC CTC trial

Clin Cancer Res

Sandoval JL, Kiavue N, Djerroudi L, Jacot W, Bachelot T, Bourgeois H, Goncalves A, Brain E, Pierga JY, Alix-Panabieres C, Berger F, Dureau S, Bidard FC

doi: 10.1158/1078-0432.CCR-25-0807

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial